Abstract
Circulating levels of the pro-inflammatory cytokine C-C motif chemokine 11 (CCL11, also known as eotaxin-1) are increased in several animal models of neuroinflammation, including traumatic brain injury and Alzheimer’s disease. Increased levels of CCL11 have also been linked to decreased neurogenesis in mice. We hypothesized that circulating CCL11 levels would increase following ischemic stroke in mice and humans, and that higher CCL11 levels would correlate with poor long-term recovery in patients. As predicted, circulating levels of CCL11 in both young and aged mice increased significantly 24 h after experimental stroke. However, ischemic stroke patients showed decreased CCL11 levels compared to controls 24 h after stroke. Interestingly, lower post-stroke CCL11 levels were predictive of increased stroke severity and independently predictive of poorer functional outcomes in patients 12 months after ischemic stroke. These results illustrate important differences in the peripheral inflammatory response to ischemic stroke between mice and human patients. In addition, it suggests CCL11 as a candidate biomarker for the prediction of acute and long-term functional outcomes in ischemic stroke patients.
Similar content being viewed by others
References
Rothenberg ME, Maclean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med. 1997;185(4):785–90.
Emanuele E, Falcone C, D’angelo A. Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. Atherosclerosis. 2006;186(1):140–5.
Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(6):1452–7.
Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest. 2006;116(1):228–36.
Adar T, Shteingart S, Ben Ya’acov A, Bar-gil Shitrit A, Goldin E. From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol. 2014;153(1):199–208.
Targowski T, Jahnz-rózyk K, Plusa T, Glodzinska-wyszogrodzka E. Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol. 2005;15(4):277–82.
Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90–4.
Shein SL, Shellington DK, Exo JL, et al. Hemorrhagic shock shifts the serum cytokine profile from pro- to anti-inflammatory after experimental traumatic brain injury in mice. J Neurotrauma. 2014;31(16):1386–95.
Manwani B, Liu F, Xu Y, Persky R, Li J, Mccullough LD. Functional recovery in aging mice after experimental stroke. Brain Behav Immun. 2011;25(8):1689–700.
Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;34(5):433–54.
Manwani B, Friedler B, Verma R, Venna VR, Mccullough LD, Liu F. Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke. 2014;45(2):571–8.
Flurkey K, Currer JM, Harrison DE. The mouse in aging research. In: Fox JG, editor. The mouse in biomedical research. 2nd ed. Burlington: College Laboratory Animal Medicine (Elsevier); 2007. p. 637–72.
Huber AK, Giles DA, Segal BM, Irani DN. An emerging role for eotaxins in neurodegenerative disease. Clin Immunol. 2016.
Menzies-gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169(5):2712–8.
Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277(5334):2005–7.
De Paulis A, Annunziato F, Di Gioia L, et al. Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol. 2001;124(1–3):146–50.
Erickson MA, Morofuji Y, Owen JB, Banks WA. Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells. J Pharmacol Exp Ther. 2014;349(3):497–507.
Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274–84.
Di Battista AP, Rhind SG, Hutchison MG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation. 2016;13(1):40.
Kitaura M, Nakajima T, Imai T, et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem. 1996;271(13):7725–30.
Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol. 1998;153(1):31–7.
Chung KF, Patel HJ, Fadlon EJ, et al. Induction of eotaxin expression and release from human airway smooth muscle cells by IL-1beta and TNFalpha: effects of IL-10 and corticosteroids. Br J Pharmacol. 1999;127(5):1145–50.
Garcia-zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2(4):449–56.
Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7(11):836–43.
Miyamasu M, Misaki Y, Yamaguchi M, et al. Regulation of human eotaxin generation by Th1-/Th2-derived cytokines. Int Arch Allergy Immunol. 2000;122(Suppl 1):54–8.
Acknowledgements
This work was funded by the National Institutes of Health NS094543 and NS076293 (to LDM), the Hartford Hospital Research Department, and the Russell and Diana Hawkins Family Foundation Discovery Fellowships to the Graduate School at UTHealth (to MAR) and the National Institutes of Health 1F30NS098628 (to MAR).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
All sample collection performed in studies involving human participants were conducted in accordance with the ethical standards of the Institutional Review Board at Hartford Hospital and the University of Connecticut Health Center and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
All applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. All animal procedures were performed in accordance with the NIH guidelines for the care and use of laboratory animals and approved by the Animal Care Committee of the University of Connecticut Health Center.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Funding
This study was funded by the National Institutes of Health NS094543 and NS076293 (to LDM) and the Hartford Hospital Research Department, and the Russell and Diana Hawkins Family Foundation Discovery Fellowships to the Graduate School at UTHealth (to MAR) and the National Institutes of Health 1F30NS098628 (to MAR).
Conflict of Interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Supplementary Figure 1
(DOCX 69 kb)
Supplementary Figure 2
(DOCX 56 kb)
Supplementary Table 1
(DOCX 13 kb)
Supplementary Table 2
(DOCX 14 kb)
Rights and permissions
About this article
Cite this article
Roy-O’Reilly, M., Ritzel, R.M., Conway, S.E. et al. CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke. Transl. Stroke Res. 8, 578–584 (2017). https://doi.org/10.1007/s12975-017-0545-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12975-017-0545-3